Ian W. Flinn, MD, PhD, discusses the mechanism of action and toxicity profile of duvelisib (IPI-145). Duvelisib is being studied for the treatment of hematologic malignancies.
Clinical Pearls
Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, discusses the mechanism of action and toxicity profile of duvelisib (IPI-145). Duvelisib is being studied for the treatment of hematologic malignancies.
Duvelisib inhibits both delta and gamma isoform.
The hope is that the molecule targets both the tumor cell as well as the microenvironment.
The toxicity profile of duvelisib is still being studied.
To date, the molecule appears to have a similar toxicity profile of other PI3K inhibitors.
